Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2012
|
| gptkbp:ATCCode |
L01XE21
|
| gptkbp:CASNumber |
755037-03-7
|
| gptkbp:chemicalFormula |
C21H15ClF4N4O3
|
| gptkbp:genericName |
gptkb:regorafenib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Stivarga
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Bayer
|
| gptkbp:mechanismOfAction |
multi-kinase inhibitor
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
anorexia fatigue hypertension hand-foot skin reaction |
| gptkbp:synonym |
gptkb:regorafenib
|
| gptkbp:usedFor |
gptkb:gastrointestinal_stromal_tumor
colorectal cancer hepatocellular carcinoma |
| gptkbp:bfsParent |
gptkb:Bayer_HealthCare
gptkb:Bayer_HealthCare_Pharmaceuticals |
| gptkbp:bfsLayer |
6
|